KR20020074461A - 가수분해 가능한 폴리(에틸렌 글리콜) 카르바메이트 유도체 - Google Patents
가수분해 가능한 폴리(에틸렌 글리콜) 카르바메이트 유도체 Download PDFInfo
- Publication number
- KR20020074461A KR20020074461A KR1020027008184A KR20027008184A KR20020074461A KR 20020074461 A KR20020074461 A KR 20020074461A KR 1020027008184 A KR1020027008184 A KR 1020027008184A KR 20027008184 A KR20027008184 A KR 20027008184A KR 20020074461 A KR20020074461 A KR 20020074461A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- poly
- formula
- substituted
- biologically active
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33344—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carbamate group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/71—Monoisocyanates or monoisothiocyanates
- C08G18/711—Monoisocyanates or monoisothiocyanates containing oxygen in addition to isocyanate oxygen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2210/00—Compositions for preparing hydrogels
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/82—Subcellular parts of microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biological Depolymerization Polymers (AREA)
Abstract
Description
Claims (35)
- 하기의 화학식을 갖는 화합물:[상기 식 중에서,POLY는 수용성, 비펩티드성 중합체이고;L은 가수분해적으로 안정한 결합 기이며;Ar은 방향족 기이고;X는 생물학적 활성 작용제의 부분구조(moiety)와 반응하여 카르바메이트 결합을 형성할 수 있는 활성화 기임].
- 제 1항에 있어서, 상기 POLY가 약 200 내지 약 100,000 Da의 분자량을 갖는 폴리(에틸렌 글리콜) 또는 그의 유도체임을 특징으로 하는 화합물.
- 제 1항에 있어서, 상기 POLY는 OH, 알콕시 및 하기 화학식을 갖는 기로 이루어진 군으로부터 선택된 보호기를 추가로 포함함을 특징으로 하는 화합물:[상기 식 중에서,L'는 가수분해적으로 안정한 결합기이고, Ar'는 방향족 기이며, X'는 생물학적 작용제의 부분구조와 반응하여 카르바메이트를 형성할 수 있는 활성화 기임].
- 제 1항에 있어서, L이 에테르, 아민, 이미드, 에스테르, 아미드, 카르바미드, 이미드 및 티오에테르로 이루어진 군으로부터 선택된 결합기를 포함함을 특징으로 하는 화합물.
- 제 1항에 있어서, L이 -O- 또는 -HN-CO- 임을 특징으로 하는 화합물.
- 제 1항에 있어서, Ar이 페닐, 치환된 페닐, 비페닐, 치환된 비페닐, 다환식 아릴, 치환된 다환식 아릴, 헤테로사이클 아릴 및 치환된 헤테로사이클 아릴임을 특징으로 하는 화합물.
- 제 1항에 있어서, 상기 X가 할로겐, N-숙신이미딜옥시, 1-벤조트리아자졸릴옥시 및 p-니트로페닐옥시로 이루어진 군으로부터 선택됨을 특징으로 하는 화합물.
- 하기의 화학식을 갖는 화합물:[상기 식중에서,L은 -O- 또는 -NHCO-이며;POLY는 -OH, 알콕시 및 하기 화학식을 갖는 기로 이루어진 기로부터 선택된 보호기를 갖는 폴리(에틸렌 글리콜)임:(상기 식중에서, L은 상술한 바와 같음)].
- 하기의 화학식을 갖는 화합물.[상기 식 중에서,POLY는 수용성 및 비펩티드성 중합체이고;L은 가수분해적으로 안정한 결합기이며;Ar은 방향족 기이고;Y는 가수분해성 활성 작용제임].
- 제 9항에 있어서, 상기 POLY가 약 200 내지 약 100,000 Da의 분자량을 갖는폴리(에틸렌 글리콜) 또는 그의 유도체임을 특징으로 하는 화합물.
- 제 9항에 있어서, 상기 POLY는 OH, 알킬 및 하기 화학식을 갖는 기로 이루어진 군으로부터 선택된 보호기를 더 포함함을 특징으로 하는 화합물:[상기 식 중에서,L'는 가수분해성 안정한 결합기이고, Ar'는 방향족 기이며, Y'는 생물학적 작용제의 부분구조와 반응하여 카르바메이트를 형성할 수 있는 활성화 기임].
- 제 9항에 있어서, L이 에테르, 아민, 이미드, 에스테르, 아미드, 카르바미드, 이미드 및 티오에테르로 이루어진 군으로부터 선택된 결합기를 포함함을 특징으로 하는 화합물.
- 제 9항에 있어서, L이 -O- 또는 -HN-CO- 임을 특징으로 하는 화합물.
- 제 9항에 있어서, Ar이 페닐, 치환된 페닐, 비페닐, 치환된 비페닐, 다환식 아릴, 치환된 다환식 아릴, 헤테로사이클 아릴 및 치환된 헤테로사이클 아릴임을 특징으로 하는 화합물.
- 제 9항에 있어서, Y가 단백질, 펩티드, 아미노리피드, 아미노기를 갖는 다당, 아미노-올리고뉴클레오타이드 및 아미노기를 갖는 약학적 작용제로 이루어진 군으로부터 선택됨을 특징으로 하는 화합물.
- 하기의 화학식을 갖는 화합물:[상기 식 중에서,L은 -O- 또는 -NHCO-이고;Y는 생물학적 활성 작용제이며;POLY는 -OH, C1-4알콕시 및 하기의 화학식을 갖는 기로 이루어진 군으로부터 선택된 보호기를 갖는 폴리(에틸렌 글리콜)임:(상기 식 중에서, Y 및 L은 상술한 바와 같음)].
- 하기의 화학식을 갖는 화합물:[상기 식중에서, Y는 방향족 기를 갖는 생물학적 활성 작용제이고, Ar은 생물학적 활성 작용제 Y의 방향족 기이며, POLY는 수용성, 비페티드성 중합체임].
- 가수분해성 카르바메이트 결합을 통해서 가교결합제에 결합된 골격을 포함하며, 가수분해성 히드로겔(hydrogel)로서, 상기 골격은 둘 이상의 아미노기를 포함하고, 상기 가교결합제는 하기의 기로 이루어진 군으로부터 선택됨을 특징으로 하는 히드로겔:및[상기 식 중에서,POLY는 수용성, 비펩티드성 중합체이고;L 및 L'는 가수분해적으로 안정한 결합이며;Ar 및 Ar'는 방향족 기이고;Z는 중심 분지형 코아(core) 부분구조이며;n은 약 2 내지 약 100 사이이고;X 및 X'는 상기 아미노기와 반응하여, 상기 가수분해성 카르바메이트 결합을 형성할 수 있는 활성화 기임].
- 제 18항에 있어서, 상기 POLY가 20,000 이상의 분자량을 갖는 폴리(에틸렌 글리콜) 또는 이의 유도체임을 특징으로 하는 히드로겔.
- 제 18항에 있어서, L 및 L'가 에테르, 아민, 이미드, 에스테르, 아미드, 카르바메이트 및 티올에스테르로 이루어진 군으로부터 선택된 결합기를 가짐을 특징으로 하는 히드로겔.
- 제 18항에 있어서, L 및 L'가 -O- 또는 -HNCO-임을 특징으로 하는 히드로겔.
- 제 18항에 있어서, Ar 및 Ar'는 페닐, 치환된 페닐, 비페닐, 치환된 비페닐, 다환식 아릴, 치환된 다환식 아릴, 헤테로사이클 아릴 및 치환된 헤테로사이클 아릴로 이루어진 군으로부터 선택됨을 특징으로 하는 히드로겔.
- 제 18항에 있어서, X 및 X'는 할로겐, N-숙신이미딜옥시, 1-벤조트리아졸릴옥시, 1-이미다졸릴옥시 및 p-니트로페닐옥시로 이루어진 군으로부터 선택됨을 특징으로 하는 히드로겔.
- 제 18항에 있어서, 상기 골격이 단백질, 펩티드, 아미노카르보히드레이트, 아미노리피드, 폴리(비닐아민), 폴리리신, 폴리(에틸렌 글리콜)아민, 둘이상의 아미노기를 갖는 약학적 작용제 및 그의 유도체로 이루어진 군으로부터 선택됨을 특지응로 하는 히드로겔.
- 제 18항에 있어서, Z가 리신, 글리세롤, 펜타에리트리톨 및 소르비톨, 및 그의 올리고머로 이루어진 군으로부터 선택됨을 특징으로 하는 히드로겔.
- 가수분해성 히드로겔 내에 담지된 생물학적 활성 작용제를 포함하는 생물학적 활성 작용제의 전달용 전달계로서, 상기 히드로겔은 가수분해성 카르바메이트 결합을 통해 가교결합제에 결합되는 골격을 포함하고, 상기 골격은 둘이상의 아미노기를 가지며, 상기 가교결합제는 하기의 기로 이루어진 군으로부터 선택됨을 특징으로 하는 전달계.및[상기 식 중에서,POLY는 수용성, 비펩티드성 중합체이고;L 및 L'는 가수분해성 안정한 결합이며;Ar 및 Ar'는 방향족 기이고;Z는 중심 분지형 코아 부분구조이며;n은 약 2 내지 약 100 사이이고;X 및 X'는 상기 아미노기와 반응하여, 상기 가수분해성 카르바메이트 결합을 형성할 수 있는 활성화 기임].
- 제 26항에 있어서, 상기 POLY가 폴리(에틸렌 글리콜) 또는 그의 유도체임을 특징으로 하는 전달 시스템.
- 제 26항에 있어서, L 및 L'가 -O- 또는 -HNCO-임을 특징으로 하는 전달 시스템.
- 제 26항에 있어서, Ar 및 Ar'는 페닐, 치환된 페닐, 비페닐, 치환된 비페닐,다환식 아릴, 치환된 다환식 아릴, 헤테로사이클 아릴 및 치환된 헤테로사이클 아릴로 이루어진 군으로부터 선택됨을 특징으로 하는 전달 시스템.
- 제 26항에 있어서, X 및 X'는 할로겐, N-숙신이미딜옥시임을 특징으로 하는 전달 시스템.
- 제 26항에 있어서, 상기 골격이 단백질, 펩티드, 아미노카르보히드레이트, 아미노리피드, 폴리(비닐아민), 폴리리신, 폴리(에틸렌 글리콜)아민, 둘 이상의 아미노기를 갖는 약학적 작용제 및 그의 유도체로 이루어진 군으로부터 선택됨을 특징으로 하는 전달 시스템.
- 제 26항에 있어서, Z가 리신, 글리세롤, 펜타에리트리톨 및 소르비톨, 및 그의 올리고머로 이루어진 군으로부터 선택됨을 특징으로 하는 전달 시스템.
- 제 26항에 있어서, 상기 생물학적 활성 작용제가 히드로겔에 공유결합됨을 특징으로 하는 전달 시스템.
- 생물학적 활성 작용제에 의한 포유동물의 치료방법으로서, 제 9항의 프로드럭을 포함하는 조성물을 제공하고, 상기 조성물을 포유동물에게 투여하는 것을 포함함을 특징으로 하는 방법.
- 생물학적 활성 작용제에 의한 포유동물의 치료방법으로서, 제 26항의 전달 시스템을 제공하고, 상기 전달 시스템을 포유동물에게 투여하는 것을 포함함을 특징으로 하는 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/469,418 | 1999-12-23 | ||
US09/469,418 US6413507B1 (en) | 1999-12-23 | 1999-12-23 | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020074461A true KR20020074461A (ko) | 2002-09-30 |
KR100748052B1 KR100748052B1 (ko) | 2007-08-09 |
Family
ID=23863712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027008184A KR100748052B1 (ko) | 1999-12-23 | 2000-12-08 | 가수분해 가능한 폴리(에틸렌 글리콜) 카르바메이트 유도체 |
Country Status (11)
Country | Link |
---|---|
US (8) | US6413507B1 (ko) |
EP (1) | EP1259262B1 (ko) |
JP (1) | JP5031164B2 (ko) |
KR (1) | KR100748052B1 (ko) |
AT (1) | ATE356638T1 (ko) |
AU (1) | AU782032B2 (ko) |
CA (1) | CA2394716C (ko) |
DE (1) | DE60033969T2 (ko) |
ES (1) | ES2281368T3 (ko) |
MX (1) | MXPA02006220A (ko) |
WO (1) | WO2001047562A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100968280B1 (ko) * | 2008-02-13 | 2010-07-06 | 가자마 이엔티 (주) | 이비인후과용 의료장치 |
Families Citing this family (185)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
US7883693B2 (en) * | 1995-12-18 | 2011-02-08 | Angiodevice International Gmbh | Compositions and systems for forming crosslinked biomaterials and methods of preparation of use |
KR100619612B1 (ko) * | 1999-10-04 | 2006-09-01 | 넥타르 테라퓨틱스 에이엘, 코포레이션 | 폴리머 안정화 신경펩타이드 |
US7074878B1 (en) | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
US6413507B1 (en) * | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
US7053150B2 (en) | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
US7091186B2 (en) * | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
EP2236161A1 (en) | 2001-10-18 | 2010-10-06 | Nektar Therapeutics | Polymer conjugates of opioid antagonists |
CA2470524A1 (en) | 2001-12-21 | 2003-07-24 | David S. Soane | Use of oligomers and polymers for drug solublization, stabilization, and delivery |
WO2003061577A2 (en) * | 2002-01-18 | 2003-07-31 | Biogen Idec Ma Inc. | Polyalkylene glycol with moiety for conjugating biologically active compound |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
EP2298278B1 (en) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prevention and reduction of blood loss and inflammatory response |
SE0201874D0 (sv) * | 2002-06-19 | 2002-06-19 | Biosensor Applications Sweden Ab Publ | Coated metal surface on solid support for displacement reactions |
GB0218827D0 (en) * | 2002-08-13 | 2002-09-18 | Syngenix Ltd | Anaesthetic compounds and conjugates thereof |
KR20050074493A (ko) * | 2002-10-21 | 2005-07-18 | 라모트 앳 텔-아비브 유니버시티 리미티드 | 칼륨 채널 및/또는 피질 뉴우런 작용 조절제로서 유용한n-페닐안트라닐산 및/또는 2-벤즈이미다졸론의 유도체 |
US7632866B2 (en) | 2002-10-21 | 2009-12-15 | Ramot At Tel Aviv University | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators |
WO2004043396A2 (en) * | 2002-11-09 | 2004-05-27 | Nobex Corporation | Modified carbamate-containing prodrugs and methods of synthesizing same |
EP1581582B2 (en) | 2003-01-06 | 2017-06-07 | Nektar Therapeutics | Thiol-selective water-soluble polmer derivatives |
US7553930B2 (en) * | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
US20050221443A1 (en) * | 2003-01-06 | 2005-10-06 | Xencor, Inc. | Tumor necrosis factor super family agonists |
US20060014248A1 (en) * | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
US20050130892A1 (en) * | 2003-03-07 | 2005-06-16 | Xencor, Inc. | BAFF variants and methods thereof |
JP4789618B2 (ja) * | 2003-02-24 | 2011-10-12 | 株式会社Nrlファーマ | 新規転写因子、その製法および用途 |
US7871607B2 (en) * | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20090123367A1 (en) * | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
JP4464395B2 (ja) * | 2003-03-05 | 2010-05-19 | ヘイローザイム インコーポレイテッド | 可溶性ヒアルロニダーゼ糖タンパク質(sHASEGP)、その調製プロセス、使用およびそれを含む薬学的組成物 |
US7642340B2 (en) | 2003-03-31 | 2010-01-05 | Xencor, Inc. | PEGylated TNF-α variant proteins |
EP1610825A2 (en) * | 2003-03-31 | 2006-01-04 | Xencor, Inc. | Methods for rational pegylation of proteins |
US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
CA2530113C (en) | 2003-06-26 | 2013-08-13 | Control Delivery Systems, Inc. | Bioerodible sustained release drug delivery systems |
DE602004016995D1 (de) | 2003-06-26 | 2008-11-20 | Control Delivery Sys Inc | In-situ gelierendes arzneimittelabgabesystem |
EP1651163B1 (en) * | 2003-08-01 | 2015-03-04 | Biocon Limited | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same |
CA3050564A1 (en) * | 2003-08-29 | 2005-03-10 | Dyax Corp. | Poly-pegylated protease inhibitors |
AU2004279895A1 (en) | 2003-10-10 | 2005-04-21 | Xencor, Inc | Protein based TNF-alpha variants for the treatment of TNF-alpha related disorders |
US7534902B2 (en) * | 2003-11-14 | 2009-05-19 | Wisconsin Alumni Research Foundation | Fluorescence assays with improved sensitivity |
CN1925875A (zh) | 2003-12-16 | 2007-03-07 | 尼克塔治疗亚拉巴马公司 | 化学改性的小分子 |
US20060182692A1 (en) | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
AU2005319099B2 (en) | 2004-02-02 | 2010-09-16 | Ambrx, Inc. | Modified human growth hormone |
GB2429207A (en) | 2004-02-02 | 2007-02-21 | Ambrx Inc | Modified human interferon polypeptides and their uses |
JP4805911B2 (ja) * | 2004-03-15 | 2011-11-02 | ネクター セラピューティクス | Hiv侵入阻害剤のポリマー系組成物及び複合体 |
KR101699142B1 (ko) * | 2004-06-18 | 2017-01-23 | 암브룩스, 인코포레이티드 | 신규 항원-결합 폴리펩티드 및 이의 용도 |
WO2006019904A1 (en) | 2004-07-14 | 2006-02-23 | University Of Utha Research Foundation | Netrin-related compositions and uses |
EP1771573A4 (en) * | 2004-07-21 | 2009-02-18 | Ambrx Inc | BIOSYNTHETIC POLYPEPTIDES OBTAINED FROM NON-NATURALLY CITED AMINO ACIDS |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
US7612153B2 (en) * | 2004-10-25 | 2009-11-03 | Intezyne Technologies, Inc. | Heterobifunctional poly(ethylene glycol) and uses thereof |
EP1836298B1 (en) | 2004-12-22 | 2012-01-18 | Ambrx, Inc. | COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF |
US8080391B2 (en) | 2004-12-22 | 2011-12-20 | Ambrx, Inc. | Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer |
US7816320B2 (en) | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
US7517914B2 (en) | 2005-04-04 | 2009-04-14 | Boston Scientificscimed, Inc. | Controlled degradation materials for therapeutic agent delivery |
US8273339B2 (en) * | 2005-04-12 | 2012-09-25 | Nektar Therapeutics | Polymer-based compositions and conjugates of antimicrobial agents |
PT1881850E (pt) | 2005-05-13 | 2010-11-26 | Lilly Co Eli | Compostos peguilados de glp-1 |
US20060263328A1 (en) * | 2005-05-19 | 2006-11-23 | Sang Van | Hydrophilic polymers with pendant functional groups and method thereof |
ATE529442T1 (de) | 2005-06-03 | 2011-11-15 | Ambrx Inc | Verbesserte humane interferon-moleküle und ihre verwendungen |
EP1896082B1 (en) | 2005-06-16 | 2012-12-26 | Nektar Therapeutics | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
WO2006138463A2 (en) * | 2005-06-17 | 2006-12-28 | Nektar Therapeutics Al, Corporation | Polymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs |
FR2887883B1 (fr) | 2005-06-29 | 2007-08-31 | Lab Francais Du Fractionnement | Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines |
KR101354244B1 (ko) | 2005-07-29 | 2014-02-18 | 넥타르 테라퓨틱스 | 폴리(에틸렌 글리콜) 의 카르보네이트 에스테르를 제조하는방법 |
PT2339014E (pt) | 2005-11-16 | 2015-10-13 | Ambrx Inc | Métodos e composições compreendendo aminoácidos não-naturais |
KR101513732B1 (ko) * | 2006-02-21 | 2015-04-21 | 넥타르 테라퓨틱스 | 분할된 분해가능한 폴리머 및 이로부터 제조된 컨주게이트 |
GB0604187D0 (en) * | 2006-03-02 | 2006-04-12 | Fusion Antibodies Ltd | Peptide and uses thereof |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
US8288339B2 (en) | 2006-04-20 | 2012-10-16 | Amgen Inc. | GLP-1 compounds |
US7560588B2 (en) | 2006-04-27 | 2009-07-14 | Intezyne Technologies, Inc. | Poly(ethylene glycol) containing chemically disparate endgroups |
GB0611405D0 (en) * | 2006-06-09 | 2006-07-19 | Univ Belfast | FKBP-L: A novel inhibitor of angiogenesis |
US8268948B2 (en) * | 2006-07-21 | 2012-09-18 | Nektar Therapeutics | Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom |
WO2008030614A2 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Suppressor trna transcription in vertebrate cells |
DK2615108T3 (en) * | 2006-09-08 | 2017-01-30 | Ambrx Inc | Modified human plasma polypeptide or fc scaffolds and their applications |
EP2114458B1 (en) | 2006-12-27 | 2014-02-26 | Nektar Therapeutics | Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage |
KR101442867B1 (ko) * | 2006-12-27 | 2014-09-25 | 넥타르 테라퓨틱스 | 제거될 수 있는 결합을 지니는 인자 ⅸ 부분중합체 컨주게이트 |
LT2842967T (lt) | 2007-01-18 | 2017-02-27 | Eli Lilly And Company | Beta amiloido pegilintas fab |
WO2008116913A2 (en) * | 2007-03-28 | 2008-10-02 | Novo Nordisk A/S | Peptide compounds with transient biodegradable pegylation |
KR20140012199A (ko) | 2007-03-30 | 2014-01-29 | 암브룩스, 인코포레이티드 | 변형된 fgf-21 폴리펩티드 및 그 용도 |
CN103965347B (zh) * | 2007-05-02 | 2017-07-18 | Ambrx公司 | 经修饰干扰素β多肽和其用途 |
CA2696208A1 (en) * | 2007-08-21 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
CN101868443A (zh) | 2007-09-20 | 2010-10-20 | 特拉维夫大学拉莫特有限公司 | N-苯基邻氨基苯甲酸衍生物及其用途 |
US20100303753A1 (en) * | 2007-10-19 | 2010-12-02 | Nektar Therapeutics | Oligomer Conjugates of Lidocaine and Its Derivatives |
EP2222329A1 (en) * | 2007-11-09 | 2010-09-01 | Baxter International Inc. | Modified recombinant factor viii and von willebrand factor and methods of use |
AU2008326324B9 (en) | 2007-11-20 | 2012-11-15 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
EP2067494A1 (en) | 2007-12-04 | 2009-06-10 | Charité-Universitätsmedizin Berlin | Sheet or tubular structure consisting of elastic biocompatible material and its use |
EP3103880A1 (en) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
AU2009223313A1 (en) * | 2008-03-14 | 2009-09-17 | Egen, Inc. | Biodegradable cross-linked branched poly (alkylene imines) |
EP2285402A2 (en) | 2008-04-14 | 2011-02-23 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
ES2587400T3 (es) | 2008-04-29 | 2016-10-24 | Ascendis Pharma Growth Disorders Division A/S | Compuestos de hormona de crecimiento humana recombinante pegilada |
UA118536C2 (uk) | 2008-07-23 | 2019-02-11 | Амбркс, Інк. | Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування |
US8575102B2 (en) * | 2008-08-01 | 2013-11-05 | Nektar Therapeutics | Conjugates having a releasable linkage |
KR101660059B1 (ko) * | 2008-08-22 | 2016-09-26 | 박스알타 인코퍼레이티드 | 중합체 벤질 카르보네이트-유도체 |
US20110171165A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of opioid growth factor peptides |
WO2010033227A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of thymosin alpha 1 peptides |
US20110206633A1 (en) * | 2008-09-19 | 2011-08-25 | Nektar Therapectics | Polymer conjugates of cd-np peptides |
EP2340050A2 (en) * | 2008-09-19 | 2011-07-06 | Nektar Therapeutics | Polymer conjugates of aod-like peptides |
WO2010033222A2 (en) * | 2008-09-19 | 2010-03-25 | Netkar Therapeutics | Polymer conjugates of ziconotide peptides |
EP2344200A2 (en) * | 2008-09-19 | 2011-07-20 | Nektar Therapeutics | Modified therapeutics peptides, methods of their preparation and use |
US20110171164A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
MX2011003117A (es) | 2008-09-19 | 2011-04-21 | Nektar Therapeutics | Conjugados polimericos de peptidos terapeuticos. |
EP2334333A1 (en) * | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of v681-like peptides |
US20110171166A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of osteocalcin peptides |
US20110171161A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of protegrin peptides |
US20110165112A1 (en) * | 2008-09-19 | 2011-07-07 | Nektar Therapeutics | Polymer conjugates of c-peptides |
EP2340047A1 (en) * | 2008-09-19 | 2011-07-06 | Nektar Therapeutics | Polymer conjugates of kiss1 peptides |
EP3216800A1 (en) | 2008-09-26 | 2017-09-13 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
MX348657B (es) | 2008-09-26 | 2017-06-21 | Ambrx Inc | Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales. |
WO2010045321A2 (en) | 2008-10-15 | 2010-04-22 | Baxter International Inc. | Pegylation of recombinant blood coagulation factors in the presence of bound antibodies |
WO2010067378A2 (en) | 2008-12-08 | 2010-06-17 | Reliance Life Sciences Pvt. Ltd. | Hydrogel composition |
DK3037529T3 (da) | 2008-12-09 | 2019-05-20 | Halozyme Inc | Udvidede opløselige ph20-polypeptider og anvendelse deraf |
AU2010203712A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
JP5604714B2 (ja) * | 2009-02-24 | 2014-10-15 | 学校法人立命館 | 両端アミド型ヒドロゲル化剤 |
EP2459224B1 (en) | 2009-07-27 | 2016-06-01 | Baxalta GmbH | Blood coagulation protein conjugates |
SG10201401194VA (en) | 2009-07-27 | 2014-07-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
CA2769340C (en) | 2009-07-31 | 2018-09-11 | Harald Rau | Prodrugs comprising an insulin linker conjugate |
CA2769162C (en) | 2009-07-31 | 2017-12-05 | Ascendis Pharma As | Biodegradable polyethylene glycol based water-insoluble hydrogels |
SG178195A1 (en) | 2009-07-31 | 2012-03-29 | Sanofi Aventis Deutschland | Long acting insulin composition |
JP5734985B2 (ja) | 2009-09-17 | 2015-06-17 | バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA | ヒアルロニダーゼおよび免疫グロブリンの安定な共製剤およびそれらの使用方法 |
WO2011057133A1 (en) | 2009-11-09 | 2011-05-12 | Spotlight Technology Partners Llc | Fragmented hydrogels |
NZ599524A (en) | 2009-11-09 | 2014-04-30 | Spotlight Technology Partners Llc | Polysaccharide based hydrogels |
CN102711733A (zh) | 2009-12-15 | 2012-10-03 | 阿森迪斯药物股份有限公司 | 瞬时连接于聚合物载体的干生长激素组合物 |
CN102753573A (zh) | 2009-12-21 | 2012-10-24 | Ambrx公司 | 经过修饰的牛促生长素多肽和其用途 |
NZ600363A (en) | 2009-12-21 | 2014-07-25 | Ambrx Inc | Modified porcine somatotropin polypeptides and their uses |
AR079345A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
LT2521568T (lt) | 2010-01-06 | 2018-12-10 | Dyax Corp. | Plazmos kalikreiną surišantys baltymai |
EP2525831B1 (en) | 2010-01-22 | 2019-05-15 | Ascendis Pharma A/S | Carrier-linked carbamate prodrug linkers |
JP5977229B2 (ja) * | 2010-05-05 | 2016-08-24 | プロリンクス リミテッド ライアビリティ カンパニー | 巨大分子共役体からの徐放 |
US9878046B2 (en) | 2010-07-20 | 2018-01-30 | Halozyme, Inc. | Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects |
KR102269494B1 (ko) | 2010-07-30 | 2021-06-25 | 박스알타 인코퍼레이티드 | 옥심 결합용 친핵성 촉매 |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
BR112013003522B1 (pt) | 2010-08-17 | 2021-05-25 | Ambrx, Inc. | polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira |
EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
ES2562643T5 (es) | 2010-09-30 | 2019-05-24 | Astrazeneca Ab | Conjugado de naloxol-peg cristalino |
WO2012054861A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Glp-1 polymer conjugates having a releasable linkage |
WO2012054822A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Pharmacologically active polymer-glp-1 conjugates |
NZ612320A (en) | 2010-12-22 | 2015-06-26 | Baxter Healthcare Sa | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
US20120196933A1 (en) * | 2010-12-23 | 2012-08-02 | Richard Franklin | Mexiletine prodrugs |
BR112013017080A8 (pt) | 2011-01-06 | 2023-05-09 | Dyax Corp | Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente |
US8440309B2 (en) | 2011-01-31 | 2013-05-14 | Confluent Surgical, Inc. | Crosslinked polymers with the crosslinker as therapeutic for sustained release |
WO2012109387A1 (en) | 2011-02-08 | 2012-08-16 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
CA3012117A1 (en) | 2011-05-27 | 2012-12-06 | Baxalta Incorporated | Fusions of psa with serpins and other therapeutic proteins |
US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
CN103889443A (zh) | 2011-06-17 | 2014-06-25 | 哈洛齐梅公司 | 使用透明质酸降解酶的持续皮下胰岛素输注法 |
CA2843503C (en) | 2011-08-12 | 2020-12-22 | Ulrich Hersel | Polymeric hyperbranched carrier-linked prodrugs |
WO2013024047A1 (en) | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
EP2741782B1 (en) | 2011-08-12 | 2020-05-06 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
US20130071394A1 (en) | 2011-09-16 | 2013-03-21 | John K. Troyer | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use |
CA2849192C (en) | 2011-10-12 | 2019-09-24 | Ascendis Pharma Ophthalmology Division A/S | Prevention and treatment of ocular conditions |
AU2012328880B2 (en) | 2011-10-24 | 2017-02-23 | Halozyme, Inc. | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof |
IL298330A (en) | 2011-12-30 | 2023-01-01 | Halozyme Inc | Ph20 polypeptide variants, formulations and uses thereof |
EA031986B1 (ru) | 2012-04-04 | 2019-03-29 | Галозим, Инк. | Способ и комбинация для лечения солидной раковой опухоли и набор, содержащий комбинацию |
AU2013204754C1 (en) | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
EP3505534A1 (en) | 2012-06-08 | 2019-07-03 | Sutro Biopharma, Inc. | Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use |
ES2611788T3 (es) | 2012-06-26 | 2017-05-10 | Sutro Biopharma, Inc. | Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso |
BR112015004022B1 (pt) | 2012-08-31 | 2023-04-25 | Sutro Biopharma, Inc | Aminoácidos modificados compreendendo um grupo azido |
MX363462B (es) | 2012-10-11 | 2019-03-25 | Ascendis Pharma As | Diagnostico, prevencion y tratamiento de enfermedades de la articulacion. |
US9278124B2 (en) | 2012-10-16 | 2016-03-08 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
JP6358661B2 (ja) * | 2013-03-19 | 2018-07-18 | 公立大学法人首都大学東京 | 界面活性剤様化合物 |
TW201534726A (zh) | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ph20玻尿酸酶變異體及其用途 |
US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
WO2015081891A1 (en) | 2013-12-06 | 2015-06-11 | Baikang (Suzhou) Co., Ltd | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
EP2949687B1 (en) | 2014-05-29 | 2016-10-19 | Dow Global Technologies Llc | Water feed methods to control mw distribution and byproducts of the carbamylation of urea |
HUE043847T2 (hu) | 2014-08-28 | 2019-09-30 | Halozyme Inc | Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia |
EA201700181A1 (ru) | 2014-10-14 | 2017-09-29 | Галозим, Инк. | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования |
KR20240024362A (ko) | 2014-10-24 | 2024-02-23 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 fgf-21 폴리펩티드 및 그의 용도 |
EP3220892B1 (en) | 2014-11-21 | 2021-10-13 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms |
BR112018011622A2 (pt) | 2015-12-11 | 2018-11-27 | Dyax Corp | método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae |
JP6925579B2 (ja) * | 2016-03-31 | 2021-08-25 | 日油株式会社 | 環状ベンジリデンアセタール構造を有する生分解性ヒドロゲル |
US10988529B2 (en) | 2016-08-09 | 2021-04-27 | Eli Lilly And Company | Combination therapy |
CN110637027A (zh) | 2017-02-08 | 2019-12-31 | 百时美施贵宝公司 | 包含药代动力学增强子的修饰的松弛素多肽及其用途 |
US10781435B2 (en) | 2017-06-22 | 2020-09-22 | Catalyst Biosciences, Inc. | Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use |
WO2019063958A1 (en) | 2017-09-27 | 2019-04-04 | The University Of York | BIOCONJUGATION OF POLYPEPTIDES |
WO2019222435A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
US20220056093A1 (en) | 2018-09-11 | 2022-02-24 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
EP3867265A1 (en) | 2018-10-19 | 2021-08-25 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
EP3902913A1 (en) | 2018-12-28 | 2021-11-03 | Catalyst Biosciences, Inc. | Modified urokinase-type plasminogen activator polypeptides and methods of use |
US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
BR112021015832A2 (pt) | 2019-02-12 | 2022-01-18 | Ambrx Inc | Composições que contêm conjugados de anticorpo-agonista de tlr, métodos e usos dos mesmos |
BR112021020023A2 (pt) * | 2019-04-05 | 2021-12-07 | Prolynx Llc | Ligantes de conjugação melhorados |
CA3166509A1 (en) | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Biased il2 muteins methods and compositions |
KR20220151202A (ko) | 2020-03-11 | 2022-11-14 | 암브룩스, 인코포레이티드 | 인터류킨-2 폴리펩타이드 접합체 및 그의 사용 방법 |
JP2023538071A (ja) | 2020-08-20 | 2023-09-06 | アンブルックス,インコーポレイテッド | 抗体-tlrアゴニストコンジュゲート、その方法及び使用 |
CA3213805A1 (en) | 2021-04-03 | 2022-10-06 | Feng Tian | Anti-her2 antibody-drug conjugates and uses thereof |
CN114209824B (zh) * | 2021-11-09 | 2023-06-20 | 淮阴工学院 | 用于肿瘤渗透增强性光热与化疗联合使用的阿霉素前药及其制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4760057A (en) | 1983-06-23 | 1988-07-26 | Merck & Co., Inc. | (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs |
GB8430252D0 (en) | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
EP0470128B2 (en) | 1989-04-19 | 2003-08-13 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
FR2676058B1 (fr) | 1991-04-30 | 1994-02-25 | Hoechst Lab | Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers. |
US5413992A (en) | 1992-07-31 | 1995-05-09 | The Scripps Research Institute | Daunomycin derivative with reduced cytotoxicity toward normal cells |
DE4236237A1 (de) | 1992-10-27 | 1994-04-28 | Behringwerke Ag | Prodrugs, ihre Herstellung und Verwendung als Arzneimittel |
US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US20020064546A1 (en) * | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
US6258351B1 (en) * | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
US6011042A (en) * | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
CA2312975C (en) * | 1997-12-17 | 2012-08-21 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US6413507B1 (en) * | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
-
1999
- 1999-12-23 US US09/469,418 patent/US6413507B1/en not_active Expired - Lifetime
-
2000
- 2000-12-08 MX MXPA02006220A patent/MXPA02006220A/es active IP Right Grant
- 2000-12-08 WO PCT/US2000/033581 patent/WO2001047562A2/en active IP Right Grant
- 2000-12-08 DE DE60033969T patent/DE60033969T2/de not_active Expired - Lifetime
- 2000-12-08 ES ES00984208T patent/ES2281368T3/es not_active Expired - Lifetime
- 2000-12-08 AU AU20869/01A patent/AU782032B2/en not_active Expired
- 2000-12-08 KR KR1020027008184A patent/KR100748052B1/ko active IP Right Grant
- 2000-12-08 JP JP2001548150A patent/JP5031164B2/ja not_active Expired - Lifetime
- 2000-12-08 EP EP00984208A patent/EP1259262B1/en not_active Expired - Lifetime
- 2000-12-08 AT AT00984208T patent/ATE356638T1/de active
- 2000-12-08 CA CA2394716A patent/CA2394716C/en not_active Expired - Lifetime
-
2001
- 2001-04-21 US US09/842,514 patent/US6541015B2/en not_active Expired - Lifetime
- 2001-04-26 US US09/842,977 patent/US6514491B1/en not_active Expired - Lifetime
- 2001-04-26 US US09/842,976 patent/US6461602B2/en not_active Expired - Lifetime
-
2003
- 2003-02-10 US US10/361,451 patent/US6899867B2/en not_active Expired - Lifetime
-
2005
- 2005-01-10 US US11/033,547 patent/US7060259B2/en not_active Expired - Lifetime
-
2006
- 2006-04-28 US US11/414,456 patent/US7608253B2/en not_active Expired - Lifetime
-
2009
- 2009-09-14 US US12/559,320 patent/US7988956B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100968280B1 (ko) * | 2008-02-13 | 2010-07-06 | 가자마 이엔티 (주) | 이비인후과용 의료장치 |
Also Published As
Publication number | Publication date |
---|---|
AU782032B2 (en) | 2005-06-30 |
US6541015B2 (en) | 2003-04-01 |
CA2394716C (en) | 2012-02-21 |
US7060259B2 (en) | 2006-06-13 |
KR100748052B1 (ko) | 2007-08-09 |
US20010046481A1 (en) | 2001-11-29 |
DE60033969D1 (de) | 2007-04-26 |
MXPA02006220A (es) | 2002-12-13 |
US20060193823A1 (en) | 2006-08-31 |
JP5031164B2 (ja) | 2012-09-19 |
US20040013637A1 (en) | 2004-01-22 |
US6461602B2 (en) | 2002-10-08 |
US7608253B2 (en) | 2009-10-27 |
EP1259262B1 (en) | 2007-03-14 |
AU2086901A (en) | 2001-07-09 |
US20010027212A1 (en) | 2001-10-04 |
WO2001047562A8 (en) | 2003-10-23 |
US20100105946A1 (en) | 2010-04-29 |
US7988956B2 (en) | 2011-08-02 |
US6899867B2 (en) | 2005-05-31 |
ATE356638T1 (de) | 2007-04-15 |
WO2001047562A3 (en) | 2002-09-12 |
JP2003518526A (ja) | 2003-06-10 |
ES2281368T3 (es) | 2007-10-01 |
DE60033969T2 (de) | 2007-12-20 |
EP1259262A1 (en) | 2002-11-27 |
US6413507B1 (en) | 2002-07-02 |
US20050147583A1 (en) | 2005-07-07 |
CA2394716A1 (en) | 2001-07-05 |
WO2001047562A2 (en) | 2001-07-05 |
US6514491B1 (en) | 2003-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100748052B1 (ko) | 가수분해 가능한 폴리(에틸렌 글리콜) 카르바메이트 유도체 | |
US7018624B2 (en) | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels | |
US6214966B1 (en) | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution | |
US6624246B2 (en) | Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol) | |
JP2003518178A (ja) | 水溶性ポリマーの立体的に妨害される誘導体 | |
US20050158273A1 (en) | Soluble, degradable polyethylene glycol) derivatives for controllable release of bound molecules into solution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120727 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20130729 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140730 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160629 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170629 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180628 Year of fee payment: 12 |